Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bca2c17a970298b94630baaa7877cf59f> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bca2c17a970298b94630baaa7877cf59f NCIT_P378 "NCI" @default.
- Bca2c17a970298b94630baaa7877cf59f type Axiom @default.
- Bca2c17a970298b94630baaa7877cf59f annotatedProperty IAO_0000115 @default.
- Bca2c17a970298b94630baaa7877cf59f annotatedSource NCIT_C85475 @default.
- Bca2c17a970298b94630baaa7877cf59f annotatedTarget "A chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, zolbetuximab specifically targets and binds to CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa." @default.